Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study suggested that low hippocampal content of SLC1A2 is a potential biomarker of epilepsy and may affect the function of neurons through the glutamatergic synapse pathway.© 2018 IUBMB Life, 71(1):213-222, 2019.
|
30360015 |
2019 |
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
GLT-1 dysregulation occurs in various neurological diseases including Huntington's disease (HD), Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and epilepsy.
|
31338020 |
2019 |
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We used immunohistochemistry, synaptosomal fractionation and Western blot analysis at 1, 3, 7 and 30 days post-IHKA induced status epilepticus (SE) to examine changes in GLT-1 and GLAST immunoreactivity and synaptosomal expression during the development of epilepsy.
|
31158434 |
2019 |
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent studies in our laboratory suggested that a dysfunction in the activity of the mouse astrocytic glutamate transporter 1 (GLT-1) could contribute to epilepsy in LD.
|
31108086 |
2019 |
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we review the role of astrocytes in epilepsy development (a.k.a. epileptogenesis), particularly astrocyte pathologies related to: aquaporin 4, the inwardly rectifying potassium channel Kir4.1, monocarboxylate transporters MCT1 and MCT2, excitatory amino acid transporters EAAT1 and EAAT2, and glutamine synthetase.
|
30022509 |
2019 |
Epilepsy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism.
|
30937933 |
2019 |
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The consequences of GLT1 dysfunction vary between different brain regions, suggesting that the role of GLT1 dysfunction in epilepsy may also vary with brain regions.
|
29214672 |
2018 |
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that SB203580 could regulate epileptic seizures via EAAT2.
|
30429824 |
2018 |
Epilepsy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overall, these results suggest that up-regulation of GLT-1 by inhibiting Hsp90β in reactive astrocytes may be a potential therapeutic target for the treatment of epilepsy and excitotoxicity.
|
28028152 |
2017 |
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reduced expression and function of these transporters, especially EAAT2, has been reported in numerous neurological disorders, including amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, schizophrenia and epilepsy.
|
25064045 |
2015 |
Epilepsy
|
0.400 |
Biomarker
|
disease |
CTD_human |
Abnormal expressions of glutamate transporters and metabotropic glutamate receptor 1 in the spontaneously epileptic rat hippocampus.
|
19853022 |
2010 |